How — and why — Houston is building a scalable life sciences ecosystem Houston has long been recognized as a world-class medical city, anchored by the Texas Medical Center, Rice University, and other clinical care and

Houston has long been a global medical center — now it’s building a scalable platform that’s transforming medicine. In a recent STAT Brand Studio virtual event, national leaders discussed how Houston’s infrastructures are converging to accelerate innovation.

Read more: shorturl.at/r8S92

Empowering patients to shape the future of MASH care The views and opinions expressed in this article and accompanying video are those of the panelists and do not necessarily reflect the views of Madrigal. A

Dr. Stephen Harrison believed patients should be at the center of research. A new MASH advocacy fellowship is continuing that work—led by the Fatty Liver Foundation with support from Madrigal Pharmaceuticals.

Read more: www.statnews.com/sponsor/2025...

The complexity of treating blood cancers and relentless pursuit of a cure Some 25 years ago, the landscape of blood cancer treatment looked dramatically different. Chemotherapy and immunomodulatory drugs defined the standard of

Advances in targeted therapies are changing the trajectory of blood cancers. Innovators in the field are focusing on building combinable regimens, expanding care beyond academic centers and designing treatments that better fit the lives of people with cancer.

Here’s how: tinyurl.com/y4r9a5r3

The Nucleus × SBS — Part 1: How proteomics is helping predict disease years in advance In the first of a three-part collaboration with Regeneron's The Nucleus podcast, the Regeneron Genetics Center’s Chief Sequencing Officer, John Overton,

Proteomics is adding a new layer to disease prediction that is revealing early signals long before symptoms.

In a collaboration with Regeneron's The Nucleus podcast, John Overton discusses how combining protein data with genomics could reshape how we approach prevention.

tinyurl.com/4x3j7ry4

China’s rise in biotech isn’t happening in a vacuum.

At STAT@JPM26, Incubate’s John Stanford pointed to U.S. policy as a likely factor, with pricing pressure and uncertainty shaping where investors place their bets.

The stakes cross the entire biopharma ecosystem: www.youtube.com/watch?v=MpAd...

STAT Brand Studio editor Jesse McQuarters is onsite at STAT’s Breakthrough Summit East in New York, with upcoming sponsored conversations featuring NYU Langone, Regeneron, Jazz Pharma, and Amneal Pharmaceuticals.

Congratulations to Brittany Whitmore of STAT Brand Studio, recognized as one of the “Significant Women in Branded Content” by the Native Advertising Institute.

Rethinking immunology: From complex diseases to new paths of care For people living with immune-mediated inflammatory diseases (IMIDs), symptoms can become part of daily life in ways that are often invisible to others.

For people living with immune-mediated inflammatory diseases (IMIDs), symptomatology can become part of daily life in ways that can be invisible to others. One leader aims to change the paradigm, combining science and data to transform how IMID's are understood and treated.
tinyurl.com/3f2rdre5

Could U.S. policy clinch China’s grip on biotech? Health care policy often carries unintended consequences. The Inflation Reduction Act’s “pill penalty,” for example, gave small-molecule drugs — which

China might ’win’ biotech. U.S. policy could be why.
MFN price controls and patent fees aren’t just squeezing large manufacturers. They’re pushing early-stage innovation (and investors) offshore. John Stanford of Incubate breaks down what’s at stake.
Watch more: www.statnews.com/sponsor/2026...

Gynecologic cancers are overlooked, and their research is underfunded. Leaders urge change Gynecologic cancers affect more than 100,000 women in the U.S. each year, yet remain among the most under-researched and underfunded cancer types. As a

"Whatever is being built has to be with the patient,” said @Maimah Karmo, founder of the @Tigerlily Foundation. “Every patient is a world in his or herself that could have ideas to transform health care. Listen to us … lean into us, learn from us, and let us lead.”

Read more:

Astellas CEO talks transformative medicines driving growth This post is sponsored by Astellas At the 2026 JPM Conference in San Francisco, Astellas President and CEO Naoki Okamura spoke with STAT Brand Studio

At JPM 2026, Astellas CEO Naoki Okamura talked strategy, science, and what it means to put patients at the center of VALUE creation. From post-patent planning to partnerships and new R&D focus areas, the company is shaping its next era of innovation.

Read more:

2026

Cancer care shouldn’t require a road trip.

At #STATASH 2025, McKesson + Texas Oncology shared how community oncology is bringing trials, next-gen therapies, and AI support into local clinics.

Read more: www.statnews.com/sponsor/2026...

The biotech betting big on ion channel science When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the

Science storytelling done right.
This deep dive into ion channel biotech Xenon pairs complex biology with an illustration built from layered paper, glass, and light — designed to invite curiosity.
🔗 www.statnews.com/sponsor/2026...

The biotech betting big on ion channel science When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the

The illustration for this @STATBrandStudio feature uses paper — cut by hand & machine — to map neural pathways. The artwork is a reminder that neuroscience is ultimately about being human.
🔗 www.statnews.com/sponsor/2026...

The biotech betting big on ion channel science When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the

This piece explores why Xenon Pharmaceuticals is betting big on ion channel science, and the art behind it is just as thoughtful: hand-cut paper neural pathways, layered, non-reflective glass, and 13 colored strands bringing the brain to life.
🔗 www.statnews.com/sponsor/2026...

Join the STAT Brand Studio crew as they recap the J.P. Morgan conference, which brought together leaders across health care, biotech, and investment to examine where innovation, capital, and care delivery are headed next. For more, check out www.statnews.com/jpm-conferen....

Genentech, *the* original biotech company, is celebrating its 50th anniversary in 2026. VP, US External Affairs Joy Russell stopped by the STAT Brand Studio multimedia lounge at #statsummit to talk with Britt Whitmore about the company's past, present, future, and its patient impact.

STAT 10 Year Anniversary When we named ourselves “STAT’’ 10 years ago, we conceded, “It takes a bit of chutzpah to name a digital-age life-sciences publication after a buzzword

STAT is 10!

Join us in reflecting on a decade of reporting from the frontiers of health and medicine.

We’re proud that since 2015 we’ve delivered urgent, authoritative, and impactful journalism.

Celebrate with us: www.statnews.com/stat-10th-an...
#STAT10 🧵

On its 10th anniversary, health care site STAT is flourishing - Poynter STAT proves a sharp concept and patient money can beat the odds in a brutal news economy

www.poynter.org/business-wor...

As global biotech competition intensifies and new R&D centers emerge, Boston faces a pivotal moment. Can it continue to lead the world in life sciences?

Join us for an in-person event in Cambridge, MA next month to find out!

www.statnews.com/event/local-...

At #STATBreakthrough Summit West, SBS spoke with Boston Scientific’s CMO about 3 AI use cases in cardiology — from scaling ECG data to spotting heart failure early.

We also discussed the intersection of evidence-based medicine and AI:

www.statnews.com/sponsor/2025...

@statnews.com #cardiology

STAT@ASCO 2025 ASCO 2025: The Latest in Cancer Research The ASCO annual meeting is widely considered one of the largest and most prestigious cancer research conferences

STAT is going to #ASCO25!

STAT reporters will be on the ground, delivering breaking oncology news and insights to help you stay ahead.

Here’s how to follow our coverage and connect with us during ASCO.

Explore all our offerings here: www.statnews.com/asco-2025/

SBS Event: Rethinking Innovation for Patients with Rare and Complex Chronic Diseases

www.statnews.com/event/rare-a...

SBS Event: Rethinking Innovation for Patients with Rare and Complex Chronic Diseases

www.statnews.com/event/rare-a...

Virtual Event | Rethinking Innovation for Patients with Rare and Complex Chronic Diseases Join STAT and Takeda on March 25 to explore how plasma-derived therapies are reshaping health care. Register now for this virtual event.

Expanding the scope of innovation is key to unlocking progress in health care. This STAT Brand Studio event will examine how a holistic approach to innovation is reshaping the development and delivery of solutions to benefit patients.

Join us live tomorrow!

A new, iterative model of drug discovery using AI After its founding in 1976, scientists at Genentech worked methodically toward the development of its first biotechnology product. It was nearly a decade

Biotherapeutic discovery has a low success rate, but Genentech aims to speed up and scale this process by using AI to transform the traditional, sequential drug discovery model into a cyclical and iterative one.

City of Hope’s president on accelerated growth, clinical trials, and emerging microbiome research One of the largest and most advanced cancer research and treatment organizations in the U.S., City of Hope is a global leader in innovative research and

www.statnews.com/sponsor/2024/12/23/city-...

Over the past two years, City of Hope has significantly expanded, transforming cancer care and improving patient access. At the STAT Summit, Marcel van den Brink, M.D., Ph.D., highlighted their clinical trial network, novel therapies, and research on the microbiome's role in immune response.

Fighting colorectal cancer disparities with real-world data STAT Brand Studio · Episode

Colorectal cancer remains the 2nd leading cause of cancer deaths, with disparities in screening and care access posing major challenges. At the 2024 STAT Summit, Dr. Angie Nicholas and Dr. Fola May discussed how data and collaboration is driving efforts to close these gaps.

www.statnews.com/sponsor/2024...